BETAPREDICT - MS Patients Treated With BETAferon: PREDICTors of Treatment Adherence

Trial Profile

BETAPREDICT - MS Patients Treated With BETAferon: PREDICTors of Treatment Adherence

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms BETAPREDICT
  • Sponsors Bayer
  • Most Recent Events

    • 10 Nov 2016 Planned End Date changed from 1 Mar 2019 to 1 Sep 2019.
    • 10 Nov 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Jun 2019.
    • 11 May 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top